Autoimmune diseases occur when the immune system mistakenly attacks healthy tissues. A key driver of this process are B cells, which can turn into plasma cells that produce harmful antibodies. These antibodies fuel symptoms like muscle weakness in myasthenia gravis or inflammation in lupus.
Telitacicept is designed to stop this process at its source by blocking two signals – BAFF and APRIL – that normally keep B cells alive and active.
By shutting down these signals, telitacicept has the potential to result in:
Unlike older treatments that broadly suppress the immune system, telitacicept is designed to quiet only the harmful pathways while leave the rest of your immune defenses ready to protect you.
